Pathology: mHCC - 1st line (L1);
| mHCC - 1st line (L1) | |||||||||
| IMbrave-150, 2020 | COSMIC-312, 2023 | CARES-310, 2023 | EMERALD-1, 2024 | CheckMate 459, 2019 | LEAP 002, 2023 | ORIENT-32, 2021 | RATIONALE 301, 2024 | ||
| durvalumab plus bevacizumab | 1 | T1 | |||||||
| Tislelizumab | 1 | T1 | |||||||
| atezolizumab plus cabozantinib | 1 | T1 | |||||||
| camrelizumab based treatment | 1 | T1 | |||||||
| pembrolizumab plus lenvatinib | 1 | T1 | |||||||
| sintilimab | 1 | T1 | |||||||
| atezolizumab plus bevacizumab | 1 | T1 | |||||||
| nivolumab alone | 1 | T1 | |||||||
| placebo | 0 | T0 | |||||||
| lenvatinib | 0 | T0 | |||||||
| sorafenib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | ||